Cargando…
2’-Fucosyllactose Ameliorates Chemotherapy-Induced Intestinal Mucositis by Protecting Intestinal Epithelial Cells Against Apoptosis
BACKGROUND & AIMS: Intestinal mucositis, a severe complication of antineoplastic therapeutics, is characterized by mucosal injury and inflammation in the small intestine. Therapies for the prevention and treatment of this disease are needed. We investigated whether 2’-fucosyllactose (2’-FL), an...
Autores principales: | Zhao, Gang, Williams, Jessica, Washington, M. Kay, Yang, Yaohua, Long, Jirong, Townsend, Steven D., Yan, Fang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688723/ https://www.ncbi.nlm.nih.gov/pubmed/34607083 http://dx.doi.org/10.1016/j.jcmgh.2021.09.015 |
Ejemplares similares
-
Alleviation of Intestinal Inflammation by Oral Supplementation With 2-Fucosyllactose in Mice
por: Grabinger, Thomas, et al.
Publicado: (2019) -
Effects of Bifidobacterium with the Ability of 2′-Fucosyllactose Utilization on Intestinal Microecology of Mice
por: Mao, Bingyong, et al.
Publicado: (2022) -
2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome
por: Kim, Yeon-Ji, et al.
Publicado: (2023) -
Effect of Rotavirus Infection and 2′-Fucosyllactose Administration on Rat Intestinal Gene Expression
por: Sáez-Fuertes, Laura, et al.
Publicado: (2023) -
Amelioration of Chemotherapy-Induced Intestinal Mucositis by Orally Administered Probiotics in a Mouse Model
por: Yeung, Chun-Yan, et al.
Publicado: (2015)